Romiplostim

Romiplostim
Clinical data
Trade names	Nplate, others
Other names	AMG531
AHFS/Drugs.com	Monograph
MedlinePlus	a609008
License data	US DailyMed: Romiplostim;
Pregnancy; category	AU: B3;
Routes of; administration	Subcutaneous
ATC code	B02BX04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	1 to 34 days
Identifiers
	IUPAC name L-methionyl[human immunoglobulin heavy constant gamma 1-(227 C-terminal residues)-peptide (Fc fragment)] fusion protein with 41 amino acids peptide, (7-7′:10,10′)-bisdisulfide dimer;
CAS Number	267639-76-9 ;
IUPHAR/BPS	6974;
DrugBank	DB05332 ;
ChemSpider	none;
UNII	GN5XU2DXKV;
KEGG	D08990;
ChEMBL	ChEMBL1201832 ;
Chemical and physical data
Formula	C2634H4086N722O790S18
Molar mass	59085.01 g·mol−1
	(what is this?) (verify)

Romiplostim, sold under the brand name Nplate among others, is a fusion protein analog of thrombopoietin, a hormone that regulates platelet production.

The most common side effects in adults include headache, infections of the nose and throat, and allergic (hypersensitivity) reactions such as rash, itching and rapid swelling under the skin. The most common side effects in children include infections of the nose and throat, runny nose, cough, fever, mouth and throat pain, abdominal (belly) pain, diarrhea, rash, and bruising.